MedTrace Logo

A Study to Assess the Effects of BPN14770 on Rosuvastatin

NCT07011992 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-08-14

No results posted yet for this study

Summary

The primary objective of this study is to investigate the effects of BPN14770 on the pharmacokinetics of the breast cancer resistance protein and organic anion transporting polypeptide 1B1 substrate rosuvastatin in healthy adults.

Conditions

  • Healthy Participants

Interventions

DRUG

Rosuvastatin

Oral tablet

DRUG

BPN14770

Oral capsule

Sponsors & Collaborators

  • Shionogi

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-07-18
Primary Completion
2025-07-31
Completion
2025-08-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07011992 on ClinicalTrials.gov